Work

Add-on Trial of Clobazam in Intractable Adult Epilepsy with Plasma Level Correlations

Year: 1990

Type: article

Abstract: Clobazam, a novel benzodiazepine, was used as an add-on agent in 47 adult patients with intractable epilepsy and a variety of seizure types. A greater than 75% reduction in seizure frequency was observed in 42% (18) of the patients and a greater than 50% reduction in 65% (29) of the patients which was sustained over a mean follow-up period of 13.3 (+/- 5.6) months. Nine patients had to discontinue the drug due to minor adverse effects or increased seizures. Possible tolerance developed in 6 patients. Plasma levels of the active metabolite N-desmethylclobazam were linearly related to dosage and appeared to correlate with both therapeutic and toxic responses. Clobazam appears to be a safe and effective add-on antiepileptic for a wide variety of seizure types in intractable epilepsy.

Source: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

DOI: 10.1017/s031716710003064x

Authors: A. Guberman, M. Couture, K. Blaschuk, A. Sherwin

Institutions: Ottawa Hospital, Montreal Neurological Institute and Hospital

Language: English

Topic: Epilepsy research and treatment

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2405549230